What is a normal Premature Atrial Contraction (PAC) or Premature Ventricular Contraction (PVC) burden on a Holter monitor?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Normal PAC and PVC Burden on Holter Monitoring

The normal premature ventricular contraction (PVC) burden is considered to be less than 2,000 PVCs per 24 hours or less than 1% of total beats, while a normal premature atrial contraction (PAC) burden is not clearly defined but follows similar principles of being infrequent and not associated with symptoms or structural abnormalities.

PVC Burden Classification

PVC burden can be stratified into risk categories based on 24-hour Holter monitoring:

PVC Burden Risk Level Clinical Significance
<2,000/24h (<1%) Low Generally benign [1]
2,000-10% Intermediate May require monitoring [1]
10-15% High Minimum threshold that can result in cardiomyopathy [1]
>15% Very High Strong association with adverse outcomes [1]
≥24% Extremely High Independently associated with cardiomyopathy [1]

Clinical Implications of PVC Burden

  • Low burden (<2,000 PVCs/24h): Generally benign with 0% risk of underlying structural heart disease 2
  • Intermediate burden (2,000-10,000 PVCs/24h): 3% risk of underlying structural heart disease 2
  • High burden (>10,000 PVCs/24h): Up to 30% risk of underlying structural heart disease 2

Day-to-Day Variability in PVC Burden

It's important to note that PVC burden can vary significantly from day to day:

  • The median range of daily PVC burden across 24-hour periods is 3.6% 3
  • Individual ranges of daily PVC burden crossed thresholds of 10%, 15%, and 20% in 26.7%, 16.8%, and 6.9% of patients, respectively 3
  • Median time to detecting maximum PVC burden was 6 days 3
  • Extended monitoring (beyond 24 hours) nearly doubled the identification of patients reaching the 10% threshold 3

Prevalence of Frequent PVCs

  • The prevalence of PVC burden 5.1%-10% is approximately 4% in patients undergoing Holter monitoring 4
  • The prevalence of PVC burden >10% is approximately 5% in patients undergoing Holter monitoring 4
  • PVCs >5% are more prevalent in older individuals, males, and Caucasians 4

Clinical Evaluation Based on PVC Burden

When multiple (≥2) PVCs are detected on a standard 12-lead ECG, further evaluation is recommended:

  1. Ambulatory Holter monitoring to quantify PVC burden
  2. Echocardiogram to assess for structural heart disease
  3. Exercise stress test to evaluate if PVCs suppress with exercise 2

If the Holter shows ≥2,000 PVCs per 24 hours or episodes of non-sustained ventricular tachycardia, additional evaluation may include:

  • Contrast-enhanced cardiac MRI
  • Electrophysiology study 2

Risk Factors for Higher PVC Burden

  • Advanced age
  • Male gender
  • Caucasian ethnicity
  • Structural heart disease
  • History of heart failure 4

Clinical Significance of PACs

While specific thresholds for PAC burden are less well-defined in guidelines, PACs follow similar principles to PVCs:

  • Isolated or infrequent PACs are generally benign
  • Frequent PACs may be associated with increased risk of developing atrial fibrillation
  • PACs that trigger sustained atrial tachyarrhythmias warrant further evaluation 2

Key Takeaways

  1. Normal PVC burden is <2,000 PVCs/24h or <1% of total beats
  2. PVC burden >10% is associated with increased risk of developing cardiomyopathy
  3. Extended monitoring (beyond 24 hours) may be necessary to accurately assess true PVC burden due to day-to-day variability
  4. Risk stratification and management decisions should be based on accurate quantification of arrhythmia burden

References

Guideline

Management of Premature Ventricular Contractions (PVCs)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the appropriate management for a 64-year-old female with intermittent A-fib (atrial fibrillation) and PVCs (premature ventricular contractions)?
What is the management for a patient with more than 999.9 premature ventricular contractions (PVCs) per hour?
What is the next best treatment plan for a 39-year-old female with a past medical history of palpitations and chest pain, whose echocardiogram shows an Ejection Fraction (EF) of 63% and an extended Holter monitor reveals sinus rhythm with rare Premature Atrial Contractions (PACs), Premature Ventricular Contractions (PVCs), and Non-Sustained Ventricular Tachycardia (NSVT) with no symptoms?
Can a Holter (Holter monitor) replace an Electrocardiogram (ECG)?
What does an 83% result on a Holter (Holter monitor) mean?
What is the most appropriate intervention for a 52-year-old female with symptoms of gastroesophageal reflux disease (GERD), including acidic taste, heartburn, and regurgitation, who has not responded to antacids?
What is a non-specific T wave change on an electrocardiogram (ECG)?
At what age does neonatal breast hypertrophy typically become apparent?
What is the most appropriate treatment for nausea and vomiting in a patient with COVID-19 (Coronavirus Disease 2019) and a history of type 2 diabetes mellitus, schizophrenia, major depressive disorder, and hypertension, currently taking metformin (Metformin), losartan (Losartan), sertraline (Sertraline), and risperidone (Risperidone)?
What is the most appropriate treatment for a 69-year-old male with benign prostatic hyperplasia (BPH) symptoms, including frequent urination, nocturia, post-void dribbling, and a weak urinary stream, with an enlarged prostate and a prostate-specific antigen (PSA) level indicating elevated PSA?
What change should be made to EP's prophylactic antiemetic regimen before her second cycle of dose-dense doxorubicin (DOX) and cyclophosphamide (CTX) for breast cancer, given her history of uncontrolled nausea and vomiting despite receiving fosaprepitant (Neulasta) (a neurokinin-1 (NK-1) antagonist), ondansetron (Zofran) (a serotonin 5-HT3 antagonist), and dexamethasone (a corticosteroid)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.